Ticker brief
ATNM
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
5
authors 14d
4
crowd 14d
+0.10
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-15 → 2026-10-16 · now +0.11 (−1 bearish … +1 bullish)
Who spoke4
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @OzmosiHealth | C | · | 2 | +0.13 |
| @BiopharmIQ | B | · | 1 | +0.10 |
| @PrismMarketView | C | · | 1 | +0.10 |
| @PrismDM | A | -2.76 | 1 | +0.10 |
Recent signals5of 5 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @PrismDM | +0.10 | Actinium appointed Sean Maenpaa as SVP of Business Development. | · | tweet ↗ |
| 2026-10-16 | @PrismMarketView | +0.10 | Actinium appointed a new SVP of Business Development effective October 12. | · | tweet ↗ |
| 2026-10-16 | @BiopharmIQ | +0.10 | The post summarizes opening biotech moves and their company-specific catalysts. | · | tweet ↗ |
| 2026-10-16 | @OzmosiHealth | +0.15 | Actinium announced EANM presentations covering broad preclinical antitumor activity of ATNM-400. | · | tweet ↗ |
| 2026-10-15 | @OzmosiHealth | +0.10 | Actinium announced an EANM presentation on a first-in-human Phase 1 ATNM-400 study. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.